Related Experiment Video
Updated: Apr 4, 2026
09:16
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
8.2K
Exploring the role of PARP9 expression in AML: prognostic implications and transcriptomic insights
Abdullah Alshammari1, Abdulrahman Algarni1, Priyanka Guru2
1Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, 73222, P.O. Box 1321, Arar, 91431 Saudi Arabia.
3 Biotech
|April 3, 2026
Summary
Poly(ADP-ribose) polymerase 9 (PARP9) is highly expressed in acute myeloid leukaemia (AML), correlating with adverse risk and poor survival outcomes. This finding suggests PARP9’s potential as a biomarker in AML patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Poly(ADP-ribose) polymerase 9 (PARP9) is an interferon-inducible enzyme linked to cancer cell survival and immune signaling.
- The clinical relevance and expression patterns of PARP9 in acute myeloid leukemia (AML) remain largely uncharacterized.
- PARP9's role suggests potential as a biomarker and therapeutic target in cancer, including AML.
Purpose of the Study:
- To investigate the expression profile of PARP9 in acute myeloid leukemia (AML) patient samples.
- To analyze the clinical relevance of PARP9 expression in AML, including its association with prognostic factors and survival outcomes.
- To characterize the transcriptional landscape associated with high PARP9 expression in AML.
Main Methods:
- Analysis of transcriptomic data from public databases (TCGA-LAML, GTEx, Human Protein Atlas, DepMap, BloodSpot).
- Comparative analysis of PARP9 expression across various cancer types and hematopoietic lineages.
- Correlation analysis of PARP9 expression with AML subtypes, cytogenetic risk, and overall survival.
- In silico analysis of differentially expressed genes associated with high PARP9 expression.
Main Results:
- PARP9 expression is significantly elevated in AML compared to most non-hematologic malignancies and normal tissues.
- High PARP9 expression is observed in specific hematopoietic lineages, particularly polymorphonuclear cells.
- Increased PARP9 expression in AML correlates with specific FAB subtypes (M0, M1, M2, M4, M5), intermediate/adverse cytogenetic risk, and poorer overall survival.
- Differential gene expression analysis revealed associations with immune and cancer-related pathways, including PD-1/PD-L1 signaling.
Conclusions:
- PARP9 is consistently overexpressed in AML and linked to adverse prognostic factors and survival.
- High PARP9 expression is associated with distinct immune and hematopoietic-related transcriptional pathways in AML.
- PARP9 warrants further investigation as a potential prognostic biomarker in acute myeloid leukemia.
